KR20150006159A - Composition Comprising mung bean coat extracts for prevention or treatment of nonalcoholic fatty liver disease - Google Patents
Composition Comprising mung bean coat extracts for prevention or treatment of nonalcoholic fatty liver disease Download PDFInfo
- Publication number
- KR20150006159A KR20150006159A KR20130079553A KR20130079553A KR20150006159A KR 20150006159 A KR20150006159 A KR 20150006159A KR 20130079553 A KR20130079553 A KR 20130079553A KR 20130079553 A KR20130079553 A KR 20130079553A KR 20150006159 A KR20150006159 A KR 20150006159A
- Authority
- KR
- South Korea
- Prior art keywords
- mung bean
- fatty liver
- composition
- extract
- present
- Prior art date
Links
- 240000004922 Vigna radiata Species 0.000 title claims abstract description 110
- 235000010721 Vigna radiata var radiata Nutrition 0.000 title claims abstract description 109
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 title claims abstract description 109
- 239000000284 extract Substances 0.000 title claims abstract description 92
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title claims abstract description 44
- 230000002265 prevention Effects 0.000 title claims description 9
- 230000000694 effects Effects 0.000 claims abstract description 37
- 210000002966 serum Anatomy 0.000 claims abstract description 34
- 239000004480 active ingredient Substances 0.000 claims abstract description 24
- 108010076365 Adiponectin Proteins 0.000 claims abstract description 21
- 102000011690 Adiponectin Human genes 0.000 claims abstract description 21
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims abstract description 20
- 102000004889 Interleukin-6 Human genes 0.000 claims abstract description 20
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 20
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 19
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract description 18
- 210000005228 liver tissue Anatomy 0.000 claims abstract description 18
- 102000004127 Cytokines Human genes 0.000 claims abstract description 17
- 108090000695 Cytokines Proteins 0.000 claims abstract description 17
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 17
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims abstract description 12
- 230000028327 secretion Effects 0.000 claims abstract description 12
- 230000003908 liver function Effects 0.000 claims abstract description 8
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 4
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 27
- 208000010706 fatty liver disease Diseases 0.000 claims description 25
- 208000004930 Fatty Liver Diseases 0.000 claims description 23
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 22
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 21
- 235000013305 food Nutrition 0.000 claims description 20
- 235000013376 functional food Nutrition 0.000 claims description 16
- 230000036541 health Effects 0.000 claims description 16
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 15
- 235000009508 confectionery Nutrition 0.000 claims description 8
- 235000012149 noodles Nutrition 0.000 claims description 7
- 244000299461 Theobroma cacao Species 0.000 claims description 5
- 230000001476 alcoholic effect Effects 0.000 claims description 5
- 235000019219 chocolate Nutrition 0.000 claims description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 235000013334 alcoholic beverage Nutrition 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 235000015243 ice cream Nutrition 0.000 claims description 4
- 235000013372 meat Nutrition 0.000 claims description 4
- 235000013550 pizza Nutrition 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- 239000000287 crude extract Substances 0.000 claims description 3
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims description 2
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims description 2
- 230000036542 oxidative stress Effects 0.000 abstract description 17
- 230000007246 mechanism Effects 0.000 abstract description 9
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 230000007774 longterm Effects 0.000 abstract description 3
- 230000007935 neutral effect Effects 0.000 abstract description 3
- 239000002699 waste material Substances 0.000 abstract description 3
- 239000006227 byproduct Substances 0.000 abstract description 2
- 238000004064 recycling Methods 0.000 abstract description 2
- 206010019837 Hepatocellular injury Diseases 0.000 abstract 1
- 235000018927 edible plant Nutrition 0.000 abstract 1
- 231100000849 liver cell damage Toxicity 0.000 abstract 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 22
- 108010082126 Alanine transaminase Proteins 0.000 description 22
- 102000000018 Chemokine CCL2 Human genes 0.000 description 18
- 229940100601 interleukin-6 Drugs 0.000 description 18
- 239000010903 husk Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 210000003494 hepatocyte Anatomy 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 208000019425 cirrhosis of liver Diseases 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
- 239000011230 binding agent Substances 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000007884 disintegrant Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 235000018823 dietary intake Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 231100000234 hepatic damage Toxicity 0.000 description 4
- 230000008818 liver damage Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000005445 natural material Substances 0.000 description 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000013256 coordination polymer Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000001596 intra-abdominal fat Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229950006238 nadide Drugs 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- BKNDOJUZMXDRDL-UHFFFAOYSA-N 4-butylcyclohexa-1,5-diene-1,4-diol Chemical compound CCCCC1(O)CC=C(O)C=C1 BKNDOJUZMXDRDL-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000204795 Muraena helena Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 235000006582 Vigna radiata Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- VYTBPJNGNGMRFH-UHFFFAOYSA-N acetic acid;azane Chemical compound N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O VYTBPJNGNGMRFH-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- AZHSSKPUVBVXLK-UHFFFAOYSA-N ethane-1,1-diol Chemical compound CC(O)O AZHSSKPUVBVXLK-UHFFFAOYSA-N 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- WPHGSKGZRAQSGP-UHFFFAOYSA-N methylenecyclohexane Natural products C1CCCC2CC21 WPHGSKGZRAQSGP-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940027779 persimmon extract Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
The present invention relates to a composition for preventing or treating non-alcoholic fatty liver disease comprising mung bean bark extract as an active ingredient, and a health supplement for improving liver function.
Fatty liver disease, also called fatty liver disease, is a disease caused by abnormal accumulation of fat (triglycerides, etc.) in hepatocytes, resulting in hepatic damage. It is known that the initial condition of fatty liver disease is a simple fatty liver that recognizes only fat deposition in hepatocytes, and then the condition progresses to fatty liver (including liver fibrosis), and also cirrhosis or hepatocellular carcinoma. In general, the causes of fatty deposits in the liver include alcohol consumption, obesity, diabetes, lipid metabolism disorders, drugs (steroids, tetracyclines, etc.), Cushing's syndrome, poisoning .
The causes of fatty liver disease are largely divided into alcohol and non-alcoholic, and liver disease caused by the former is called alcoholic fatty liver disease (also called alcoholic hepatopathy) and the latter is caused by non-alcoholic fatty liver disease nonalcoholic fatty liver disease (NAFLD).
Alcoholic fatty liver disease progresses from the initial simple fatty liver to fatty liver and cirrhosis. Non-alcoholic fatty liver disease has been thought to remain in simple fatty liver and the condition does not progress. However, recently, it has been found that non-alcoholic fatty liver disease also progresses from simple fatty liver to fatty liver or liver cirrhosis.
Non-alcoholic fatty liver disease is a disease characterized by fatty changes (steatosis) and lobular hepatitis (steatohepatitis), which are hallmarks of alcoholic hepatitis in liver biopsy despite the absence of alcohol- ) And so on. The pathologic findings of the liver are diverse spectrum from non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH), fibrosis associated with fatty liver, liver cirrhosis, It is used to mean all inclusive.
Most of these nonalcoholic fatty liver diseases are accompanied by insulin resistance, obesity, diabetes and hyperlipidemia. When such complications exist, it is necessary to first perform the treatment. The principle of treatment for nonalcoholic fatty liver disease is improvement of lifestyle such as meal therapy and exercise therapy, but it is a reality that it is difficult to carry out surely. In nonalcoholic steatohepatitis, a more aggressive medication is needed because it is likely to develop into cirrhosis / hepatocellular carcinoma. Although treatment aimed at improvement of oxidative stress and insulin resistance which is thought to be important in the pathogenesis and progression of nonalcoholic fatty liver disease has been attempted, there is no established scientific method.
As described above, a sufficient therapeutic method has not been established for non-alcoholic fatty liver disease, and development of a therapeutic drug having high effectiveness against non-alcoholic fatty liver disease has been desired.
Accordingly, the inventors of the present invention sought to find a natural substance having an excellent action for improving non-alcoholic fatty liver disease without adverse effects on the living body, and focused on the mung bean bark extract and its pharmacological effects were examined. As a result, the mung bean bark extract Reduce ALT activity in this serum; Lowering the triglyceride content in liver tissue; In addition to increasing adiponectin secretion, serum TNF-α, IL-6, and MCP-1 levels are reduced by inhibiting oxidative stress, a major mechanism of hepatocyte injury. Non-alcoholic fatty liver disease Can be effectively prevented or treated.
Accordingly, an object of the present invention is to provide a composition capable of effectively preventing or treating non-alcoholic fatty liver disease without adverse effects on the living body.
Another object of the present invention is to provide a health functional food excellent in the liver function improving effect without side effects on the living body.
In order to accomplish the above object, the present invention provides a composition for preventing or treating non-alcoholic fatty liver disease comprising mung bean bark extract as an active ingredient.
In one embodiment of the present invention, the mung bean bark extract may be a crude extract, a polar solvent-soluble extract, or a non-polar soluble extract.
In one embodiment of the present invention, the mung bean bark extract reduces ALT activity in serum; Lowering the triglyceride content in liver tissue; In addition to the increased secretion of adiponectin in the serum, the action of TNF-α, IL-6, and MCP-1, which are inflammatory cytokines, may be prevented or prevented by non-alcoholic fatty liver disease.
In one embodiment of the present invention, the mung bean bark extract may be contained in an amount of 0.1 to 90% by weight based on the total weight of the composition.
In one embodiment of the present invention, the non-alcoholic fatty liver disease can be selected from the group consisting of non-alcoholic simple fatty liver, non-alcoholic fatty liver, non-alcoholic cirrhosis and hepatocellular carcinoma.
The present invention also provides a health functional food for improving liver function comprising mung bean bark extract as an active ingredient.
In one embodiment of the present invention, the food is selected from the group consisting of beverage, meat, chocolate, foods, confectionery, pizza, ram noodles, gums, candy, ice cream, alcoholic beverages, .
The mung bean bark extract of the present invention reduces ALT activity in serum; In addition to lowering the triglyceride content in liver tissue; (IL-6) and MCP-1 (inflammatory cytokines) as well as increased secretion of adiponectin by inhibiting oxidative stress, which is known to be the main mechanism of hepatocyte injury, The composition of the present invention can be usefully used for the prevention or treatment of nonalcoholic fatty liver disease. Particularly, the mung bean bark extract is a natural substance that can be edible. Therefore, the composition of the present invention containing it as an active ingredient has safety advantages even in long-term use. In addition, the mung bean husk is a by-product of mung bean that is discarded and can be economically effective not only to reduce costs, but also to be eco-friendly by recycling the waste.
FIG. 1 is a graph showing the content of alanine aminotransferase (ALT) in the serum according to the feeding of the mung bean bark extract of the present invention to the type 2 diabetic mouse.
FIG. 2 is a graph showing the measurement of the triglyceride content in liver tissues according to the feeding of the mung bean bark extract of the present invention to a mouse of type 2 diabetes mellitus.
FIG. 3A is a graph showing the concentration of adiponectin in the serum according to the feeding of the mung bean bark extract of the present invention to the type 2 diabetes model mouse.
FIG. 3B is a graph showing the concentration of TNF-.alpha. In serum according to the feeding of the mung bean bark extract of the present invention to a mouse of type 2 diabetes mellitus.
FIG. 3c is a graph showing the concentration of IL-6 in serum according to the feeding of the mung bean bark extract of the present invention to a mouse of type 2 diabetes mellitus.
FIG. 3D is a graph showing the concentration of MCP-1 in serum according to the feeding of the mung bean bark extract of the present invention to a mouse of type 2 diabetes mellitus.
The present invention relates to a novel use of mung bean bark extract, and is characterized by providing a composition for preventing or treating non-alcoholic fatty liver disease comprising mung bean bark extract as an active ingredient.
The 'Vigna radiata L.' of the present invention is an annual herbaceous plant belonging to the soybean family, and corresponds to crops widely grown in Asia, including China, including mung bean, It is also called Gidou (吉 豆). Except for mung bean husk, mung bean noodle is widely used as noodles, porridge, and stubble. The effect of mung bean is fever, and it is known to be effective in edema, diuretic, different skin diseases, acne, boils, erysipelas, prostatitis, drug poisoning, bad breath, vomiting and mumps.
However, the efficacy of mung bean coat (MBC) has not been well known. In particular, there is no study of the effect of mung bean skin on the improvement of non-alcoholic fatty liver disease.
We have found that mung bean bark extract reduces ALT activity in serum; In addition to lowering the triglyceride content in liver tissue; The inhibition of oxidative stress, which is known to be the main mechanism of hepatocyte injury, has the effect of decreasing the level of inflammatory cytokines TNF-α, IL-6 and MCP-1 as well as the increase of adiponectin secretion By identifying, it was the first time that we could effectively prevent or treat non-alcoholic fatty liver disease through these mechanisms.
In the following Example <3-1> of the present invention, the effect of the mung bean bark extract on the serum ALT activity was examined. As a result, the serum ALT activity in the experimental group (mung bean shell group) And it was deduced that the mung bean bark extract of the present invention has an activity of inhibiting liver damage (see FIG. 1).
In the following Example < 3-2 > of the present invention, the effect of the mung bean bark extract on the triglyceride content in the liver tissue was examined. As a result, in the liver tissue of the mung bean bark group Of liver oil was 165.6 ± 36.4 mg / g liver compared with that of control (218.3 ± 31.6 mg / g liver). As a result, the mung bean bark extract of the present invention showed the neutral fat content It can be effectively lowered (see Fig. 2).
In the following Example <3-3> of the present invention, the effect of mung bean bark extract on the production of serum adiponectin and inflammatory cytokine was examined. As a result, the test group (mung bean husk group) (10.6 ± 1.4 pg / mL) as compared with the control group (13.3 ± 1.9 pg / mL). Also, in the experimental group (mung bean shell group ) Were measured as 12.5 ± 1.5 (TNF-α), 22.0 ± 3.4 (IL-6) and 110.6 ± 17.7 (MCP-1) pg / mL in serum, respectively , Indicating that inflammatory cytokine levels were significantly reduced compared to the control (15.4 ± 2.0, 31.9 ± 5.3, 144.9 ± 23.9 pg / mL) (see FIG. 3).
For reference, oxidative stress is well known as a major mechanism of hepatocyte damage in hepatitis. In particular, visceral adipose tissue plays an important role in accumulating fat in hepatocytes. When fat accumulates in the body, NADPH (nicotinamide adenine di-nucleotide phosphate) oxidase is activated and systemic oxidative stress is increased. Increased oxidative stress has been shown to increase inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6), and adiponectin adiponectin) secretion. Adiponectin is an anti-inflammatory cytokine secreted mainly from adipocytes and is structurally very similar to TNF-α, but its action reversely increases insulin sensitivity, decreases glucose production in the liver, and improves hyperlipidemia It is known.
Thus, in Example <3-3> of the present invention, whether or not the mung bean husk extract can reduce the oxidative stress was verified by measurement of inflammatory cytokines and adiponectin produced (secreted) by oxidative stress, In addition, it was found that the extract supplementation can decrease TNF-α, IL-6 and MCP-1 levels, which are inflammatory cytokines, as well as increased secretion of adiponectin. .
As a result of the above-mentioned Example 3, the present inventors have found that when mung bean husk extract is fed to a mouse of type 2 diabetic model, it decreases ALT activity in serum, lowers the triglyceride content in liver tissue, (TNF-α, IL-6, and MCP-1), as well as increased secretion of adiponectin in serum.
Therefore, the composition of the present invention comprising mung bean bark extract as an active ingredient can effectively prevent or treat non-alcoholic fatty liver disease.
The mung bean bark extract according to the present invention can be obtained by extracting and separating from nature using an extraction and separation method known in the art. The 'extract' defined in the present invention can be obtained by extracting mung bean bark For example, a crude extract of mung bean husk, a polar solvent-soluble extract of mung bean husk, or a non-polar solvent-soluble extract of mung bean husk.
As an appropriate solvent for extracting the extract from the mung bean shell, water or a pharmaceutically acceptable organic solvent may be used. For example, it may be purified water, methanol, ethanol Alcohol having 1 to 4 carbon atoms, acetone, ether, benzene, chloroform, ethyl acetate (including butanol), propanol, isopropanol, ethyl acetate, methylene chloride, hexane, and cyclohexane may be used alone or in combination.
As the extraction method, any one of the methods such as hot water extraction method, cold extraction method, reflux cooling extraction method, solvent extraction method, steam distillation method, ultrasonic extraction method, elution method and compression method can be selected and used. In addition, the desired extract may be further subjected to a conventional fractionation process or may be purified using a conventional purification method. The method for producing the mung bean bark extract of the present invention is not limited and any known method can be used.
For example, the mung bean bark extract contained in the composition of the present invention can be prepared into a powdery state by an additional process such as vacuum distillation, freeze drying, or spray drying, have. Further, the primary extract can be further purified by using various chromatographies such as silica gel column chromatography, thin layer chromatography, high performance liquid chromatography and the like, You can get it.
Therefore, in the present invention, the mung bean husk extract is a concept including all the extracts, fractions and tablets obtained in each step of extraction, fractionation or purification, their diluted solutions, concentrates or dried products.
The composition of the present invention containing the mung bean bark extract as an active ingredient may be a pharmaceutical composition or a food composition.
The pharmaceutical composition of the present invention can be prepared by using pharmaceutically acceptable and physiologically acceptable adjuvants in addition to the above-mentioned active ingredients. Examples of the adjuvants include excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, A lubricant or a flavoring agent can be used.
The pharmaceutical composition may be formulated into a pharmaceutical composition containing at least one pharmaceutically acceptable carrier in addition to the above-described active ingredients for administration.
The pharmaceutical composition may be in the form of granules, powders, tablets, coated tablets, capsules, suppositories, liquids, syrups, juices, suspensions, emulsions, drops or injectable solutions. For example, for formulation into tablets or capsules, the active ingredient may be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Also, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included as a mixture. Suitable binders include, but are not limited to, natural sugars such as starch, gelatin, glucose or beta-lactose, natural and synthetic gums such as corn sweeteners, acacia, tracker candles or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum and the like. Acceptable pharmaceutical carriers for compositions that are formulated into a liquid solution include sterile solutions suitable for the living body such as saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, One or more of these components may be mixed and used. If necessary, other conventional additives such as an antioxidant, a buffer, and a bacteriostatic agent may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like. Further, it can be suitably formulated according to each disease or ingredient, using the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA as an appropriate method in the field.
In one embodiment of the present invention, the mung bean bark extract of the present invention may be contained in an amount of 0.1 to 90% by weight based on the total weight of the composition.
The non-alcoholic fatty liver which can be prevented or treated with the pharmaceutical composition of the present invention includes, but is not limited to, non-alcoholic simple fatty liver, non-alcoholic fatty liver hepatitis, nonalcoholic liver cirrhosis and hepatocellular carcinoma.
The composition of the present invention may also be a food composition. In addition to containing the active ingredient mung bean bark extract, such a food composition may contain various flavors or natural carbohydrates as an additional ingredient such as a conventional food composition.
Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. The above-described flavors can be advantageously used as natural flavorings (tau martin), stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.).
The food composition of the present invention can be formulated in the same manner as the above pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, meat, chocolates, foods, confectionery, pizza, ram noodles, other noodles, gums, candy, ice cream, alcoholic beverages, vitamin complexes, .
In addition to the mung bean bark extract, which is an effective ingredient, the food composition may also contain various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and intermediates such as cheese and chocolate, Salts of alginic acid and its salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages and the like. In addition, the food composition of the present invention may contain natural fruit juice and pulp for the production of fruit juice drinks and vegetable drinks.
The extract of mung bean bark, which is an effective ingredient of the present invention, is a natural substance and has little toxicity and side effects. Therefore, it can be safely used for long-term administration for the purpose of improving liver function.
The present invention also provides a health functional food for improving liver function comprising mung bean bark extract as an active ingredient.
The health functional food of the present invention can be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, and rings for the purpose of improving liver function.
In the present invention, the term " health functional food " refers to foods manufactured and processed using raw materials or ingredients having useful functions in accordance with Law No. 6727 on Health Functional Foods. Or to obtain a beneficial effect in health use such as physiological action.
The health functional foods of the present invention may contain conventional food additives and, unless otherwise specified, whether or not they are suitable as food additives are classified according to the General Rules for Food Additives approved by the Food and Drug Administration, Standards and standards.
Examples of the items listed in the above-mentioned "food additives" include chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; Natural additives such as persimmon extract, licorice extract, crystalline cellulose, high color pigment and guar gum; L-glutamic acid sodium preparations, noodle-added alkalis, preservative preparations, tar coloring preparations and the like.
For example, the health functional food in tablets may be prepared by granulating a mixture of mung bean bark extract, an active ingredient of the present invention, with an excipient, a binder, a disintegrant and other additives in a usual manner, Or the mixture can be directly compression molded. In addition, the health functional food of the tablet form may contain a mating agent or the like if necessary.
The hard capsule of the capsule-type health functional food can be prepared by filling a normal hard capsule with a mixture of the mung bean husk extract, which is an effective ingredient of the present invention, with an additive such as an excipient, and the soft capsule is prepared by dissolving the mung bean bark extract, And filling the mixture with a capsule base such as gelatin. The soft capsule may contain a plasticizer such as glycerin or sorbitol, a coloring agent, a preservative and the like, if necessary.
The ring-shaped health functional food can be prepared by molding a mixture of mung bean bark extract, excipient, binder, disintegrant, and the like, which is an effective ingredient of the present invention, by a conventionally known method and, if necessary, Or it may be coated with a material such as starch, talc.
The granular health functional food may be prepared by granulating a mixture of mung bean bark extract, excipient, binder, disintegrant and the like, which is an effective ingredient of the present invention, into granules by a known method, and if necessary, And the like.
The health functional food comprising the mung bean bark extract of the present invention as an active ingredient decreases ALT activity in serum as confirmed in the following examples; In addition to lowering the triglyceride content in liver tissue; In addition to the increased secretion of adiponectin in the serum, the TNF-α, IL-6, and MCP-1 levels, which are inflammatory cytokines, can be significantly reduced.
The health functional food may be a beverage, a meat, a chocolate, a food, a confectionery, a pizza, a ramen, a noodle, a gum, a candy, an ice cream, an alcoholic beverage, a vitamin complex and a health supplement food.
The present invention also provides the use of a composition comprising, as an active ingredient, a mung bean bark extract for the production of a medicament or food for the prevention or treatment of nonalcoholic fatty liver disease. The composition of the present invention comprising the mung bean bark extract as an active ingredient can be used for the manufacture of medicines or foods for the prevention or treatment of nonalcoholic fatty liver disease.
The present invention also provides a method of preventing or treating nonalcoholic fatty liver disease comprising administering to a mammal an extract of mung bean bark.
The term "mammal " as used herein refers to a mammal that is the subject of treatment, observation or experimentation, preferably a human.
The term "therapeutically effective amount " as used herein refers to the amount of active ingredient or pharmaceutical composition that induces a biological or medical response in a tissue system, animal or human, as contemplated by a researcher, veterinarian, physician or other clinician, The amount that induces the relief of the symptoms of the disease or disorder being treated. It will be apparent to those skilled in the art that the therapeutically effective dose and the number of administrations of the active ingredient of the present invention will vary depending on the desired effect. The optimal dosage to be administered can therefore be readily determined by those skilled in the art and will depend upon the nature of the disease, the severity of the disease, the amount of active and other ingredients contained in the composition, the type of formulation, and the age, , Sex and diet, time of administration, route of administration and rate of administration of the composition, duration of treatment, concurrent administration of the drug, and the like. In the treatment method of the present invention, in the case of an adult, it is preferable to administer the mung bean bark extract of the present invention at a dose of 1 mg / kg to 250 mg / kg once to several times a day.
The composition comprising the mung bean husk extract of the present invention as an active ingredient in the treatment method of the present invention can be administered orally or rectally via intravenous, intraarterial, intraperitoneal, intramuscular, intrasternal, percutaneous, topical, And can be administered in a conventional manner.
Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are for further illustrating the present invention, and the scope of the present invention is not limited to these examples.
< Example 1>
Manufacture of mung bean bark extract
The mung bean bark used in the present invention was obtained by purchasing mung bean in the market of Banyeo Dong Agricultural Products in Busan, and then separating the mung bean husk and mung bean. The freeze-dried mung bean bark was ground and 1.0 kg of ground mung bean husk powder was extracted three times at room temperature (12 h, 6 h, 3 h) with 75% ethanol corresponding to 10 times (W / V) The extract was separated by filtration. The filtrate was extracted with a rotary evaporator (EYELA FDU-1100, Japan) at 40 ° C, and 25.0 g of an extract was obtained as an extracted residue. At this time, the yield of the mung bean husk extract was 2.5%.
< Example 2>
When the mung bean bark extract of the present invention shows weight and On the dietary intake Measure impact
A 4-week-old male C57BL / Ks-db / db mouse was purchased and after an adaptation period of one week, the animals were divided into two groups according to the nude method. MUN bean coat (MBC) group was fed with 1% of the diet of mung bean bark extract for 7 weeks as ad libitum in the control group and AIN-93G group in the control group as shown in Table 1 below. Body weight and dietary intake were measured twice a week to observe changes in body weight with consumption of mung bean bark extract. The results are shown in Table 2 below.
2) Hair gongburn (Murry goulburn Co., Australia)
3) Samyangsa, Korea
4) Sigma Company, USA
5) ICN Biochemical, USA
6) CheilJedang, Korea
As a result, as shown in Table 2, the body weights of the control group and the mung bean skin group were 43.5 ± 3.5 and 41.9 ± 3.0 g, respectively, and there was no significant difference between the two groups, and the dietary intake was also significantly different between the two groups I could confirm that there was no.
< Example 3>
Effect of the present invention on the improvement of fatty liver of mung bean bark extract
To investigate the effect of the mung bean bark extract of the present invention prepared in Example 1 on the prevention of fatty liver and the improvement of fatty liver, it was investigated whether serum ALT, neutral lipid content of liver tissue and oxidative stress The concentrations of inflammatory cytokines were measured.
For this purpose, the experimental animals used in Example 2 were fasted for 12 hours after 10 weeks of dietary intake, blood was collected from the heart with a syringe containing 10 mg of EDTA (ehylene diamine tetra acetic acid) and sucking it with carbon dioxide gas. Liver tissues were rinsed with 0.9% physiological saline and drained and stored at -70 ° C until analysis. Blood was centrifuged at 3,000 × g for 15 minutes and serum was collected and stored at -70 ° C.
<3-1> Serum ALT Active measurement
When the structure and function of cell membranes are destroyed, ALT (alanine aminotransferase), an enzyme widely present in the liver cytoplasm, is released into the blood, so that ALT levels in the blood are frequently used as an index of liver damage.
In this experiment, serum ALT levels were measured to examine the effect of the mung bean bark extract of the present invention on prevention of fatty liver and improvement of fatty liver.
ALT activity was measured by quantitative kit reagent (Yeongdong Pharmaceutical, Korea). 1.0 mL of the ALT substrate solution was heated in a 37 ° C water bath for 2 minutes, then 0.2 mL of plasma was added and reacted in a 37 ° C water bath for 30 minutes. After 30 minutes, 1.0 mL of the color development reagent was added, and the mixture was allowed to stand at room temperature for 20 minutes. Then, 10.0 mL of 0.4 N NaOH was added and absorbance was measured at 505 nm. The activity of the sample was calculated by extrapolating the absorbance of the ALT standard solution (2 mM pyruvate) in the same manner as above and absorbance to the standard curve.
As a result, the serum ALT activities of the control group and the mung bean shell group were 129.3 ± 20.5 and 98.9 ± 17.8 U / L, respectively, and the serum ALT activity of the mung bean shell group was significantly decreased compared with the control group (p ≪ 0.05). The results are shown in FIG. 1, and it can be inferred that the mung bean bark extract of the present invention has an activity of inhibiting liver damage.
<3-2> Liver tissue Measurement of triglyceride content
In this experiment, the content of triglyceride in liver tissues was also measured in order to examine the effect of the mung bean bark extract of the present invention on prevention of fatty liver and improvement of fatty liver.
The triglyceride content of the liver tissues was measured by the crude fat analysis (Folch method) and by enzyme method. Take 0.1 mL of the extract from the jellyfish extract and volatilize the solvent in a heating block (Daeil tech, Korea) and dissolve in 0.2 mL of ethanol. To prevent turbidity with the reaction solution, add 3 mL of the reaction reagent dissolved in the buffer solution containing 0.5 mL of triton X-100, react at 37 ° C for 10 minutes, and measure the absorbance at 550 nm.
As a result, it was confirmed that the content of triglyceride was 165.6 ± 36.4 mg / g liver in the liver tissue of the experimental group (mung bean skin group) fed with mung bean skin, and that it was significantly decreased compared to the control group (218.3 ± 31.6 mg / g liver) (P < 0.001). The results are shown in FIG. 2, which shows that the mung bean bark extract of the present invention has an activity of lowering the triglyceride content in the liver tissue.
<3-3> Serum Adiponectin And inflammatory cytokine levels
In order to examine whether the mung bean bark extract prepared in Example 1 can reduce oxidative stress, it was verified by measurement of adiponectin and inflammatory cytokines (TNF-a, IL-6 and MCP-1).
Oxidative stress is well known as the main mechanism of hepatocyte injury in fatty liver. In particular, visceral adipose tissue plays an important role in accumulating fat in hepatocytes. When fat accumulates in the body, NADPH (nicotinamide adenine di-nucleotide phosphate) oxidase is activated and systemic oxidative stress is increased. Increased oxidative stress has been shown to increase inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6), and adiponectin adiponectin) secretion. In addition, the exact mechanism of nonalcoholic fatty liver disease has not been elucidated, but fatty liver has been described as progressing to fatty liver and liver fibrosis due to the action including inflammatory cytokine response (Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology, 114: 842-5, 1998., Day CP, From fat to inflammation, Gastroenterology.
Therefore, in order to investigate whether the mung bean bark extract can reduce oxidative stress, which is the main mechanism of hepatocyte injury, in the experiment group (mung bean shell group) ingested with the mung bean bark extract of the present invention, adiponectin and inflammatory cytokine TNF-α, IL-6, MCP-1) were measured.
Serum adiponectin (Biovender, USA), TNF- alpha (eBiosience, USA), IL-6 (eBiosience, USA) and MCP-1 (Biosource, USA) were measured using an ELISA cytokine kit according to the manufacturer's instructions .
As a result, as shown in FIG. 3A, serum adiponectin concentration in the experimental group (mung bean skin group) ingested with the mung bean bark extract of the present invention was 13.3 ± 1.9 pg / mL, which was significantly higher than that of the control group (10.6 ± 1.4 pg / mL) (P <0.05). As shown in FIGS. 3b to 3d, the concentration of TNF-α, IL-6 and MCP-1 in the serum of the experimental group (mungbean shell group) consumed with the mung bean bark extract was (15.4 ± 2.0, 31.9 ± 5.3, and 144.9 ± 23.9 pg / mL), respectively, in the control group (n = 12.5 ± 1.5 (TNF-α), 22.0 ± 3.4 (P < 0.05).
In conclusion, when the mung bean bark extract of the present invention is administered to a mouse of type 2 diabetes mellitus, the ALT activity is reduced in the serum without affecting the body weight, and the triglyceride content (TNF-α, IL-6, and MCP-1) as well as increased secretion of adiponectin in the serum according to the suppression of oxidative stress.
The present invention has been described with reference to the preferred embodiments. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. Therefore, the disclosed embodiments should be considered in an illustrative rather than a restrictive sense. The scope of the present invention is defined by the appended claims rather than by the foregoing description, and all differences within the scope of equivalents thereof should be construed as being included in the present invention.
Claims (7)
Wherein the mung bean bark extract is a crude extract, a polar solvent-soluble extract, or a non-polar soluble extract.
The mung bean bark extract reduces ALT activity in serum; Lowering the triglyceride content in liver tissue; The present invention provides a composition for preventing or treating non-alcoholic fatty liver disease, which has an effect of increasing the secretion of adiponectin in serum and reducing TNF-α, IL-6 and MCP-1 levels which are inflammatory cytokines.
The composition for prevention or treatment of nonalcoholic fatty liver disease according to claim 1, wherein the mung bean bark extract is contained in an amount of 0.1 to 90% by weight based on the total weight of the composition.
Wherein the non-alcoholic fatty liver disease is selected from the group consisting of non-alcoholic simple fatty liver, non-alcoholic fatty liver hepatitis, non-alcoholic cirrhosis, and hepatocellular carcinoma.
Wherein said food is selected from the group consisting of beverage, meat, chocolates, foods, confectionery, pizza, ramen, other noodles, gums, candy, ice cream, alcoholic beverages, vitamin complexes and health supplement foods.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130079553A KR20150006159A (en) | 2013-07-08 | 2013-07-08 | Composition Comprising mung bean coat extracts for prevention or treatment of nonalcoholic fatty liver disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130079553A KR20150006159A (en) | 2013-07-08 | 2013-07-08 | Composition Comprising mung bean coat extracts for prevention or treatment of nonalcoholic fatty liver disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150006159A true KR20150006159A (en) | 2015-01-16 |
Family
ID=52569632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR20130079553A KR20150006159A (en) | 2013-07-08 | 2013-07-08 | Composition Comprising mung bean coat extracts for prevention or treatment of nonalcoholic fatty liver disease |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20150006159A (en) |
-
2013
- 2013-07-08 KR KR20130079553A patent/KR20150006159A/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101691205B1 (en) | Composition comprising herbal extract for preventing or treating fatty liver disease | |
| US8980846B2 (en) | Composition containing styraxlignolide A or the aglycone thereof as an active ingredient for preventing or treating asthma | |
| KR101292931B1 (en) | Composition Comprising Hedyotis diffusa extract for prevention or treatment of nonalcoholic fatty liver disease | |
| KR20220132349A (en) | Composition for preventing, ameliorating or treating metabolic disease comprising leaf extract of new pepper cultivar as effective component | |
| KR101497109B1 (en) | Composition for preventing, improving, or treating a disease controlled by PPAR action | |
| KR102414431B1 (en) | A composition for improving, preventing and treating of diabetes mellitus | |
| KR101688002B1 (en) | Composition for preventing or treating liver diseases comprising sonicated ginseng berry | |
| KR20150022177A (en) | Composition comprising solvent fractionated extracts of Zingiber officinale, which are useful for the prevention, improvement and treatment of functional gastrointestinal and motility disorders | |
| KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
| KR20160070872A (en) | Composition for prevention or treatment of nonalcoholic fatty liver disease comprising Crataegi Fructus extract | |
| KR20150072660A (en) | Hepatoprotective composition containing adenophora triphylla extract | |
| KR101692604B1 (en) | Composition comprising pomegranate juice extrated low speeed for improving liver function | |
| JP2010512382A (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF DIABE CONTAINING SICONIN COMPOUND AND USE | |
| KR20140108104A (en) | Compositions comprising the combined extract of Artemisia iwayomogi and Curcuma longa for treating, inhibiting or preventing obesity-related disease | |
| KR101954891B1 (en) | A composition for treating or improving hepatic fibrosis comprising Seahorse extract | |
| KR101662887B1 (en) | Composition Comprising Actinidia arguta shoot extract for prevention or treatment of nonalcoholic fatty liver disease | |
| KR20120089045A (en) | A composition comprising powder of amphicarpaea bracteata subsp.edgeworthii(benth.) h.ohashi and the extract thereof for preventing and treating diabetes mellitus and diabetic complication | |
| KR20150072659A (en) | Hepatoprotective composition containing smilax china extract | |
| KR101724587B1 (en) | Composition for treating, improving or preventing liver injury and liver dysfunction | |
| KR20150006159A (en) | Composition Comprising mung bean coat extracts for prevention or treatment of nonalcoholic fatty liver disease | |
| KR20070060306A (en) | Pharmaceutical composition comprising shikonin derivatives from lithospermum erythrorhizon for treating or preventing diabetes mellitus | |
| KR101578404B1 (en) | Composition for prevention or treatment of cancer containing extract or fraction of Euphorbia L. | |
| KR101954890B1 (en) | A composition for treating or improving non-alcoholic fatty liver disease comprising Seahorse extract | |
| KR20140026737A (en) | A composition comprising the powder of fermented curcuma longa l. for protecting alcoholic liver damage | |
| KR20170092975A (en) | A composition for improving, preventing and treating of fatty liver diseases comprising porphyra tenera extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |